Stocks To Buy Now

Blog


DGE 4th PRC Performance Optimization Summit To Unite The Best Minds In The Business

Life science professionals responsible for promotional review, marketing, labelling, communications, and compliance are invited to attend DGE’s 4th PRC Performance Optimization Summit being held in Philadelphia June 5-6, 2024. The most detailed industry event available on this subject, participants will focus in-depth on ways to ensure the best regulatory outcomes. DGE (Dynamic Global Events), a life science leader in organizing B2B events, strives to meet the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries. DGE events specialize in offering a robust platform where professionals can network, connect, and explore business opportunities in a dynamic environment.

It is difficult to gather PRC input and maintain compliance when turnovers are high, when new technologies like AI come into play, and when team members meet virtually and regulatory decisions seem inconsistent. Industry experts will share breakthrough strategies on all these challenges, and more!

Topics of discussion:

  • Raising company awareness of the PRC brand
  • Maintaining CFL compliance
  • Planning modular content updates
  • Including AI-driven tasks into promotional review
  • Training all team members to be high performers
  • Incorporating strategies for new technologies like VR, mobile websites, and apps
  • Integrating and managing a claims matrix

Attendees can learn and network with industry leaders and gain exclusive access to the event presentation information and contacts. The DGE summit provides all the strategies and tools that PRCs require to maintain compliance for the best regulatory results.

To learn more, please visit https://ibn.fm/98ZsO.

From Our Blog

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial

June 26, 2025

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, recently reported an encouraging clinical outcome in its Phase 2 HARMONIC(TM) trial, where a patient with advanced non-small cell lung cancer (“NSCLC”) achieved a complete response using LP-300, a compound optimized through Lantern’s AI-powered platform, RADR(R) […]

Rotate your device 90° to view site.